Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.41 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.41 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.38 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.38 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.38 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 known ✓ | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.33 |
| ▸ | HTR7 known ✓ | P34969 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 7/20 | 0.61 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31018191 | 1.00 | PNMT (0.61) | PNMTCHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL31018189 | 0.98 | PNMT (0.63) | PNMTCHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL5600431 | 0.98 | PNMT (0.63) | PNMTCHRM3HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5601615 | 0.88 | PNMT (0.52) | PNMTCHRM3HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL5599748 | 0.88 | PNMT (0.52) | PNMTCHRM3HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL20854727 | 0.86 | PNMT (0.38) | PNMTCHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL20854719 | 0.83 | PNMT (0.39) | PNMTHTR2AHTR2CHTR2B | |
| SCHEMBL3095812 | 0.74 | CHRM3 (0.41) | PNMTCHRM3HTR2CADRA2AADRA2B | |
| SCHEMBL3095722 | 0.71 | PNMT (0.71) | PNMTHTR2BADRA2AADRA2BADRA2C | |
| SCHEMBL4012914 | 0.71 | CHRM3 (0.39) | PNMTCHRM3HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112437771-B | Bronchodilating heteroatom-linked amides | 阿凯德制药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11680054-B2 | Bronchodilating hetero-linked amides | ARCEDE PHARMA AB (SE) | 2023-06-20 | — | — | US | disclosed |
| EP-3818055-B1 | NOVEL BRONCHODILATING HETERO-LINKED AMIDES | RESPIRATORIUS AB PUBL (SE) | 2022-02-16 | — | — | EP | disclosed |
| US-20210139455-A1 | NOVEL BRONCHODILATING HETERO-LINKED AMIDES | ARCEDE PHARMA AB (SE) | 2021-05-13 | — | — | US | disclosed |
| EP-3818055-A1 | NOVEL BRONCHODILATING HETERO-LINKED AMIDES | Respiratorius AB (Publ) (SE) | 2021-05-12 | — | — | EP | disclosed |
| CN-112437771-A | Novel bronchodilator heteroatom-linked amides | 瑞思拜尔锐特略斯股份公司 | 2021-03-02 | — | — | CN | disclosed |
| WO-2020009653-A1 | NOVEL BRONCHODILATING HETERO-LINKED AMIDES | RESPIRATORIUS AB (PUBL) (SE) | 2020-01-09 | — | — | WO | disclosed |
| US-8318768-B2 | Bronchodilating alpha, beta-unsaturated isoquinoline amides | RESPIRATORIUS AB (SE) | 2012-11-27 | — | — | US | disclosed |
| EP-2181095-B1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | RESPIRATORIUS AB (SE) | 2012-08-22 | — | — | EP | disclosed |
| US-20100256101-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | ARCEDE PHARMA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| EP-2181095-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | Respiratorius AB (SE) | 2010-05-05 | — | — | EP | disclosed |
| WO-2009007419-A1 | NOVEL BRONCHODILATING ISOQUINOLINE CARBAMATES | RESPIRATORIUS AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007420-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | RESPIRATORIUS AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007418-A1 | NOVEL BRONCHODILATING ISOQUINOLINE AMIDES | RESPIRATORIUS AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008095852-A1 | BRONCHORELAXING ARYLAMIDES | RESPIRATORIUS AB (SE) | 2008-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11680054-B2 | Bronchodilating hetero-linked amides | PTGIS, PTGIR, ADRB2 | CHRM3 20/4885HTR2A 1290/4885HTR2C 1328/4885 |
| US-20100256101-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | PTGIS, ADRB2, ADRB1 | CHRM3 114/4885HTR2A 1243/4885HTR2C 1240/4885 |
| US-20210139455-A1 | NOVEL BRONCHODILATING HETERO-LINKED AMIDES | ADRB2, ADRB1, PTGIS | CHRM3 23/4885HTR2A 1109/4885HTR2C 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.